Aliath Bioventures | LinkedIn (original) (raw)
Entidades de capital riesgo y capital privado
Barcelona, Catalonia 739 seguidores
Sobre nosotros
Aliath Bioventures is a life sciences venture investor and advisor to AltamarCAM specialized in life sciences and healthcare markets.
Sector
Entidades de capital riesgo y capital privado
Tamaño de la empresa
De 2 a 10 empleados
Sede
Barcelona, Catalonia
Tipo
Asociación
Fundación
2023
Ubicaciones
Empleados en Aliath Bioventures
Actualizaciones
- Aliath Bioventures ha compartido esto
Mediktor is ISO 27001 certified! In collaboration with ADOK CERTIFICACIÓN, S.L. an international partner for this achievement of Alcumus we are proud to announce that we have obtained the world's most recognized standard for Information Security Management Systems (ISMS). Achieving ISO 27001 certification demonstrates Mediktors systematic and secure management of sensitive information, a practice we've maintained since our beginnings over 10 years ago. Congratulations to our team and everyone involved in this process! Contact us for a demo ➡️ https://lnkd.in/dScQM4kt #ISO27001 #ISOCertified - See you in Lille at #BioFIT2024! Our partner Philippe Monteyne is speaking at the 13th edition of @BioFIT Event during the session “Biotech investors’ forecast: Where will early-stage investment go in 2025?” to explore biotech investment trends from 2024, review key deals, and forecast where early-stage investments will be directed in 2025, focusing on geographical diversity and high-potential therapeutic areas. BioFIT is the place to be for early-stage deals and investment rounds in the #LifeSciences sector: let’s network, learn and explore the latest advances in our field! 📅 December 3rd and 4th, 2024, in Lille (France) 👉 To learn more about the event and the conference programme: https://lnkd.in/gJrr22PLooking forward to meeting you there!
- Thank you to Catalonia.Health (CataloniaBio & HealthTech) for hosting today a great conference on medical AI, where we discussed regulatory barriers, key technological and ethical challenges to achieve greater implementation and adoption in Europe. Let’s keep working towards it!
- Today Aliath's team attended the World Orphan Drug Congress joining a session on the Holistic Approach to Rare Disease Drug Development: Integrating ESG, Patient Engagement, and Commercial Strategy for Improved EU Access. A great workshop! Thanks for such a fantastic session Nicholas Brooke Sheela Upadhyaya Kieron Lewis
- We are glad to announce that our colleague Montserrat Vendrell, co-founding partner of Aliath Bioventures, participated in the BNEW - Barcelona New Economy Week #BNEW2024 and shared her insights on healthcare innovation. Montserrat joined a session moderated by Santiago de Torres, Executive President of Atrys Health, with Josep Maria Campistol, director of the Hospital Clínic de Barcelona, and Manel del Castillo Rey, director of the Hospital Sant Joan de Déu Barcelona to discuss the transformative role of new technologies in healthcare. Montserrat highlighted the critical role of investors in driving innovation, particularly in disruptive technologies such as #AI, which are revolutionising diagnostics, treatments and the sustainability of healthcare systems. She stressed the importance of analysing these disruptions to understand how the market, hospitals and patients will respond. Supporting technology in healthcare is essential as its impact is far-reaching across the system. The 5th edition of BNEW was a huge success, attracting over 12,700 professionals from 106 countries and facilitating over 10,000 networking connections across seven interconnected sectors - Digital Industry, Mobility, Sustainability, Aviation, Talent, Health and Experience - the event offered a wealth of knowledge.#Innovation #Healthcare #AI #BNEW2024 #Sustainability #Investment #Technology
- Aliath Bioventures ha compartido esto
Ayer, 10 de octubre, participamos en el encuentro BNEW - Barcelona New Economy Week en Barcelona, que reunió a expertos de los sectores más importantes con el objetivo de "𝗰𝗼𝗻𝗲𝗰𝘁𝗮𝗿, 𝗶𝗺𝗽𝘂𝗹𝘀𝗮𝗿 𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝗿 𝗹𝗮 𝗻𝘂𝗲𝘃𝗮 𝗲𝗰𝗼𝗻𝗼𝗺𝗶́𝗮”. Nuestro presidente, Santiago de Torres, moderó la mesa dedicada al sector sanitario, “Healthtech: accesible y sostenible”, que contó con la participación de Josep M. Campistol, director general del Hospital Clínic de Barcelona; Manel del Castillo Rey, director gerente del Hospital Sant Joan de Déu Barcelona; y Montserrat Vendrell, socia confundadora de Aliath Bioventures. Durante el debate, todos los participantes subrayaron el delicado momento que atraviesa el sistema sanitario debido al incremento de la demanda, la falta de profesionales y la escasa financiación, lo que está provocando dificultades de accesibilidad, sostenibilidad y equidad del servicio. Como posibles soluciones, plantearon la necesidad de una mayor adopción de la tecnología por parte del sistema, la incorporación de nuevos perfiles al sector, o un cambio de mentalidad por parte de los propios profesionales, entre otros. “Tenemos los instrumentos tecnológicos para cambiar pero nos falta determinación. Y la tecnología nos tiene que ayudar a hacer un cambio de paradigma” afirmó Josep M. Campistol. - Aliath Bioventures ha compartido esto
676 seguidores
1 mes Editado
SPA - Società Prodotti Antibiotici and Inbiomotion sign an exclusive distribution agreement for MAF Test® in ItalySPA - Società Prodotti Antibiotici, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test® for identifying high risk early-stage breast cancer patients, have signed an exclusive distribution agreement to start offering the MAF Test® in Italy. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists identify patients potentially receptive to the prevention of recurrence and who may benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated or are being treated with bisphosphonates. Thanks to this agreement, the MAF Test® could increase the survival of 8 out of 10 of the 55,000 early-stage breast cancer patients diagnosed each year in Italy.Joël Jean-Mairet, Executive Chairperson of Inbiomotion since 2012 and Executive Chairperson of Ysios Capital commented, "We are thrilled to partner with SPA - Società Prodotti Antibiotici to bring the cutting-edge MAF Test® to Italy. This collaboration represents a significant step forward in making precision medicine accessible to more patients. At Inbiomotion, our mission has always been to transform cancer treatment by providing an innovative diagnostic tool that empower both healthcare professionals and patients to make the best possible decisions. By offering a tailored approach to cancer treatment, we can significantly improve patient outcomes, reduce the likelihood of unnecessary treatments, and ultimately enhance the quality of life for those battling breast cancer. We believe that this partnership with SPA - Società Prodotti Antibiotici will play a crucial role in achieving these goals in the Italian market." # PerspectiveFromKnowledge #UncoverTheUndiscovered #CancerDiagnostics #BreastOncology #PrecisionMedicine #PatientJourneyFor more information: https://lnkd.in/dnerZKxZ
Únete para ver lo que te estás perdiendo
Páginas similares
- Asabys Partners Entidades de capital riesgo y capital privado Barcelona, Barcelona
- Alta Life Sciences Entidades de capital riesgo y capital privado Barcelona, Cataluña / Catalunya
- Ysios Capital Entidades de capital riesgo y capital privado San Sebastián, País Vasco / Euskadi
- INBRAIN Neuroelectronics Tecnología, información e internet
- Alcura Fabricación de productos farmacéuticos Viladecans, Barcelona
- Vsquared Ventures Entidades de capital riesgo y capital privado Munich, Bayern
- Invivo Partners Entidades de capital riesgo y capital privado Barcelona, Barcelona
- GENE VECTOR Investigación biotecnológica Barcelona, Catalonia
- Oryzon Genomics SA Biotecnología Cornellà de Llobregat, Catalonia
- AdBio partners Entidades de capital riesgo y capital privado Paris, IDF